DelveInsight’s, “Shigellosis Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Shigellosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from Shigellosis Pipeline Report
- DelveInsight’s Shigellosis Pipeline report depicts a robust space with 05+ active players working to develop 05+ pipeline therapies for Shigellosis treatment.
- The leading Shigellosis Companies include GlycoVaxyn, Institut Pasteur, GlaxoSmithKline, and others are evaluating novel Shigellosis drugs candidate to improve the treatment landscape.
- The promising Shigellosis therapies include S. sonnei 1790GAHB, Flexyn2a, Flexyn2a plus adjuvant, Shigella 4V, MenACWY, Rabies, Flexyn2a, Menveo, Boostrix, SC599, and others
- The companies and academics are working to assess challenges and seek opportunities that could influence Shigellosis R&D. The therapies under development are focused on novel approaches to treat/improve Shigellosis.
Get an overview of the Shigellosis Pipeline landscape @ Shigellosis Emerging Therapies
Shigellosis Overview
Shigellosis is a bacterial infection caused by a group of bacteria called Shigella. It affects the digestive system. Shigella is very contagious and spread through contaminated water and food or via contact with contaminated feces. The bacteria release toxins that irritate the intestines. The primary symptom of shigellosis is diarrhea. Shigella are usually found in the feces of infected people. The bacteria are spread when someone comes into contact with the stool of an infected person, or with something that has been contaminated with the stool or the bacteria. Contaminated food and water are also a common cause of shigellosis. The main goal of treatment is preventing dehydration for most cases of shigellosis. Treatment usually includes antibiotics to eliminate the bacteria from the digestive tract.
Latest Breakthroughs and Developments in the Shigellosis Treatment Landscape
- The University of Maryland, located in Baltimore, Maryland, has created a potential vaccine for this potentially fatal bacterial infection and is currently accepting volunteers to drink the Shigella vaccine in order to investigate whether the vaccine would stop or minimize the infection and symptoms. Every year, thousands of lives will be saved thanks to the success of this vaccination.
- It is a biconjugate (Tetravalent) vaccine. Currently, in phase II of clinical trials for the treatment of shigella infection.
Shigellosis Emerging Drugs
- Shigella 4v: GlycoVaxyn
- SF2a-TT15: Institut Pasteur
Get to know more information about Shigellosis treatment therapies @ Shigellosis Clinical Trials
Shigellosis Pipeline Therapeutics Analysis
There are approx. 5+ key companies which are developing the therapies for Shigellosis. The companies which have their Shigellosis drug candidates in the mid to advanced stage, i.e. Phase II include, GlycoVaxyn and others.
DelveInsight’s Shigellosis Pipeline Report covers around 5+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase II/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discover more about therapy set to grab substantial Shigellosis Pipeline landscape @ Shigellosis Pipeline Therapeutics Assessment
Scope of the Shigellosis Pipeline Report
- Coverage- Global
- Shigellosis Companies- GlycoVaxyn, Institut Pasteur, GlaxoSmithKline, and others
- Shigellosis therapies- S. sonnei 1790GAHB, Flexyn2a, Flexyn2a plus adjuvant, Shigella 4V, MenACWY, Rabies, Flexyn2a, Menveo, Boostrix, SC599, and others
- Shigellosis Pipeline Assessment by Product Type
- Shigellosis Pipeline Assessment by Stage and Product Type
- Shigellosis Pipeline Assessment by Route of Administration
- Shigellosis Pipeline Assessment by Stage and Route of Administration
- Shigellosis Pipeline Assessment by Molecule Type
- Shigellosis Pipeline Assessment by Stage and Molecule Type
Table of content
- Introduction
- Executive Summary
- Shigellosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Shigellosis – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Shigellosis Collaboration Deals
- Late Stage Products (Phase III)
- Drug name: Company name
- Mid Stage Products (Phase II)
- Shigella 4v: GlycoVaxyn
- Pre-clinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Shigellosis Key Companies
- Shigellosis Key Products
- Shigellosis- Unmet Needs
- Shigellosis- Market Drivers and Barriers
- Shigellosis- Future Perspectives and Conclusion
- Shigellosis Analyst Views
- Shigellosis Key Companies
- Appendix
Got Queries? Reach out for more information on the Shigellosis Pipeline Report @ Shigellosis Preclinical and Discovery Stage Products
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/